Neuburgh Advisers’s United Therapeutics UTHR Stock Holding History

Neuburgh Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.3M	Sell	16,252 -12,580	-44%	-$1.01M	0.04%	285
2019 Q2	$2.25M	Sell	28,832 -14,280	-33%	-$1.34M	0.07%	204
2019 Q1	$5.06M	Sell	43,112 -28,050	-39%	-$3.27M	0.17%	118
2018 Q4	$7.75M	Buy	71,162 +4,998	+8%	+$580K	0.3%	74
2018 Q3	$8.46M	Buy	66,164 +17,340	+36%	+$2.14M	0.27%	83
2018 Q2	$5.53M	Buy	48,824 +10,064	+26%	+$1.11M	0.18%	110
2018 Q1	$4.36M	Buy	38,760 +28,628	+283%	+$3.64M	0.15%	131
2017 Q4	$1.5M	Buy	10,132 +3,910	+63%	+$497K	0.05%	231
2017 Q3	$729K	Sell	6,222 -19,890	-76%	-$2.54M	0.03%	325
2017 Q2	$3.39M	Sell	26,112 -9,554	-27%	-$1.19M	0.13%	146
2017 Q1	$4.83M	Sell	35,666 -15,232	-30%	-$2.31M	0.19%	103
2016 Q4	$7.3M	Buy	+50,898	New	+$6.5M	0.33%	65

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Neuburgh Advisers's UTHR Position: Q3 2019 in Review

Neuburgh Advisers reduced its United Therapeutics (UTHR) stake by 44% in Q3 2019, selling an estimated $1.01M and leaving 16,252 shares worth $1.3M. The position accounts for 0.04% of the portfolio, ranked #285.

Neuburgh Advisers first reported a position in UTHR in Q4 2016 and has held it in 12 quarters since. The position peaked at $8.46M in Q3 2018. 302 funds tracked by Wall St. Rank hold UTHR as of Q3 2019.

Neuburgh Advisers held 16,252 shares of United Therapeutics worth $1.3M as of Q3 2019.
Neuburgh Advisers sold 12,580 United Therapeutics shares in Q3 2019, an estimated $1.01M.
United Therapeutics made up 0.04% of Neuburgh Advisers's portfolio in Q3 2019, its #285 holding.
Neuburgh Advisers first reported a position in United Therapeutics in Q4 2016 and has held it in 12 quarters since.
Neuburgh Advisers's United Therapeutics position peaked at $8.46M in Q3 2018.
302 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.